Jump to content

Substance dependence

From Wikipedia
substance dependence
class of disease
Subclass ofaddiction, substance use disorder, social issue, non-controlled substance abuse, disease Edit
Has causeillegal drug Edit
Studied byaddictology, addiction psychology Edit
Health specialtypsychiatry, narcology, addiction medicine Edit
Drug or therapy used for treatmentdrug harm reduction, substance abuse treatment Edit
Usescontrolled substance, illegal drug Edit
ICD-9-CM304.6, 304.60 Edit

Substance dependence, dem sanso know as drug dependence, be a biopsychological situation wer by an individual ein functionality be dependent on de necessitated re-consumption of a psychoactive substance secof an adaptive state wey develop within de individual from psychoactive substance consumption wey result in de experience of withdrawal den dey necessitate de re-consumption of de drug.[1][2] A drug addiction, a distinct concept from substance dependence, be defined as compulsive, out-of-control drug use, despite negative consequences.[1][2] An addictive drug be a drug wich both be rewarding den reinforcing.[1] ΔFosB, a gene transcription factor, wich now be known to be a critical component den common factor insyd de development of virtually all forms of behavioral den drug addictions,[3][4][5] buh no be dependence.

De International Classification of Diseases dey classify substance dependence as a mental den behavioural disorder.[6] Insyd de Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (dem release insyd 2013), na substance abuse den substance dependence be eliminated den replaced plus de single diagnosis of substance use disorders. Na dem do dis secof "de tolerance den withdrawal wey previously define dependence be actually very normal responses to prescribed medications wey affect de central nervous system wey no necessarily dey indicate de presence of an addiction."[7]

Risk factors

[edit | edit source]
Mental health as a risk factor for illicit drug dependency anaa abuse

Dependence potential

[edit | edit source]
DrugMeanPleasurePsychological dependencePhysical dependence
Heroin/Morphine3.003.03.03.0
Cocaine2.393.02.81.3
Tobacco2.212.32.61.8
Barbiturates2.012.02.21.8
Alcohol1.932.31.91.6
Ketamine 1.54 1.9 1.7 1.0
Benzodiazepines1.831.72.11.8
Amphetamine1.672.01.91.1
Cannabis1.511.91.70.8
Ecstasy1.131.51.20.7

Capture rates

[edit | edit source]
Drug% of users
Cannabis9%
Caffeine 9%
Alcohol15.4%
Cocaine16.7%
Heroin23.1%
Tobacco31.9%

References

[edit | edit source]
  1. 1 2 3 Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 364–368. ISBN 9780071481274. The defining feature of addiction is compulsive, out-of-control drug use, despite negative consequences. ...
    Addictive drugs are both rewarding and reinforcing. ... Familiar pharmacologic terms such as tolerance, dependence, and sensitization are useful in describing some of the time-dependent processes that underlie addiction. ...
    Dependence is defined as an adaptive state that develops in response to repeated drug administration, and is unmasked during withdrawal, which occurs when drug taking stops. Dependence from long-term drug use may have both a somatic component, manifested by physical symptoms, and an emotional–motivation component, manifested by dysphoria. While physical dependence and withdrawal occur with some drugs of abuse (opiates, ethanol), these phenomena are not useful in the diagnosis of addiction because they do not occur with other drugs of abuse (cocaine, amphetamine) and can occur with many drugs that are not abused (propranolol, clonidine).

    The official diagnosis of drug addiction by the Diagnostic and Statistic Manual of Mental Disorders (2000), which makes distinctions between drug use, abuse, and substance dependence, is flawed. First, diagnosis of drug use versus abuse can be arbitrary and reflect cultural norms, not medical phenomena. Second, the term substance dependence implies that dependence is the primary pharmacologic phenomenon underlying addiction, which is likely not true, as tolerance, sensitization, and learning and memory also play central roles. It is ironic and unfortunate that the Manual avoids use of the term addiction, which provides the best description of the clinical syndrome.
  2. 1 2 "Substance use disorder: MedlinePlus Medical Encyclopedia". medlineplus.gov (in English). Retrieved 2026-02-14.
  3. Robison AJ, Nestler EJ (October 2011). "Transcriptional and epigenetic mechanisms of addiction". Nature Reviews. Neuroscience. 12 (11): 623–37. doi:10.1038/nrn3111. PMC 3272277. PMID 21989194. ΔFosB has been linked directly to several addiction-related behaviors ... Importantly, genetic or viral overexpression of ΔJunD, a dominant negative mutant of JunD which antagonizes ΔFosB- and other AP-1-mediated transcriptional activity, in the NAc or OFC blocks these key effects of drug exposure14,22–24. This indicates that ΔFosB is both necessary and sufficient for many of the changes wrought in the brain by chronic drug exposure. ΔFosB is also induced in D1-type NAc MSNs by chronic consumption of several natural rewards, including sucrose, high fat food, sex, wheel running, where it promotes that consumption14,26–30. This implicates ΔFosB in the regulation of natural rewards under normal conditions and perhaps during pathological addictive-like states.
  4. Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M (2012). "Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms". Journal of Psychoactive Drugs. 44 (1): 38–55. doi:10.1080/02791072.2012.662112. PMC 4040958. PMID 22641964. It has been found that deltaFosB gene in the NAc is critical for reinforcing effects of sexual reward. Pitchers and colleagues (2010) reported that sexual experience was shown to cause DeltaFosB accumulation in several limbic brain regions including the NAc, medial pre-frontal cortex, VTA, caudate, and putamen, but not the medial preoptic nucleus. Next, the induction of c-Fos, a downstream (repressed) target of DeltaFosB, was measured in sexually experienced and naive animals. The number of mating-induced c-Fos-IR cells was significantly decreased in sexually experienced animals compared to sexually naive controls. Finally, DeltaFosB levels and its activity in the NAc were manipulated using viral-mediated gene transfer to study its potential role in mediating sexual experience and experience-induced facilitation of sexual performance. Animals with DeltaFosB overexpression displayed enhanced facilitation of sexual performance with sexual experience relative to controls. In contrast, the expression of DeltaJunD, a dominant-negative binding partner of DeltaFosB, attenuated sexual experience-induced facilitation of sexual performance, and stunted long-term maintenance of facilitation compared to DeltaFosB overexpressing group. Together, these findings support a critical role for DeltaFosB expression in the NAc in the reinforcing effects of sexual behavior and sexual experience-induced facilitation of sexual performance. ... both drug addiction and sexual addiction represent pathological forms of neuroplasticity along with the emergence of aberrant behaviors involving a cascade of neurochemical changes mainly in the brain's rewarding circuitry.
  5. Olsen CM (December 2011). "Natural rewards, neuroplasticity, and non-drug addictions". Neuropharmacology. 61 (7): 1109–22. doi:10.1016/j.neuropharm.2011.03.010. PMC 3139704. PMID 21459101.
  6. Drs; Sartorius, Norman; Henderson, A.S.; Strotzka, H.; Lipowski, Z.; Yu-cun, Shen; You-xin, Xu; Strömgren, E.; Glatzel, J.; Kühne, G.-E.; Misès, R.; Soldatos, C.R.; Pull, C.B.; Giel, R.; Jegede, R.; Malt, U.; Nadzharov, R.A.; Smulevitch, A.B.; Hagberg, B.; Perris, C.; Scharfetter, C.; Clare, A.; Cooper, J.E.; Corbett, J.A.; Griffith Edwards, J.; Gelder, M.; Goldberg, D.; Gossop, M.; Graham, P.; Kendell, R.E.; Marks, I.; Russell, G.; Rutter, M.; Shepherd, M.; West, D.J.; Wing, J.; Wing, L.; Neki, J.S.; Benson, F.; Cantwell, D.; Guze, S.; Helzer, J.; Holzman, P.; Kleinman, A.; Kupfer, D.J.; Mezzich, J.; Spitzer, R.; Lokar, J. "The ICD-10 Classification of Mental and Behavioural Disorders Clinical descriptions and diagnostic guidelines" (PDF). www.who.int World Health Organization. Microsoft Word. bluebook.doc. p. 65. Retrieved 23 June 2021 via Microsoft Bing.
  7. "Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th edition)2014 102 Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th edition) Washington, DC American Psychiatric Association 2013 xliv+947 pp. 9780890425541(hbck);9780890425558(pbck) £175 $199 (hbck); £45 $69 (pbck)". Reference Reviews. 28 (3): 36–37. 2014-03-11. doi:10.1108/rr-10-2013-0256. ISSN 0950-4125.
[edit | edit source]